Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma
Clinical trial NCT00912418 · COMPLETED
Trial details
- NCT number
- NCT00912418
- Sponsor
- Craig L Slingluff, Jr
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2000-05-01
- Primary completion
- 2002-09-17
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.